Sinovac Biotech Ltd. (SVA), a Chinese biopharmaceutical firm, said on Tuesday that it has rejected a partial tender offer by Alternative Liquidity Index LP to acquire up to 10 million shares for $0.03 per share in cash.Sinovac noted that the offer is not in the best interests of the company or its shareholders.

中国生物制药公司Sinovac Biotech Ltd.（SVA）星期二表示，已拒绝替代流动性指数LP以现金形式收购高达1000万股0.03美元的股份.Sinovac指出，该报价是不符合公司或股东的最佳利益。

The drug maker believes the implied valuation based on the offer price is less than the value of the company. In addition, Alternative Liquidity failed to show an accurate means for determining the present value of the shares of Sinovac. Sinovac believes that the offer price represents an opportunistic attempt by Alternative Liquidity to make a profit by purchasing the shares at a very low price.

药品制造商认为基于报价的隐含估值低于公司的价值。此外，替代流动性未能显示确定Sinovac股份现值的准确手段。Sinovac认为，报价代表了替代流动性通过以非常低的价格购买股票来获利的机会主义尝试。

For comments and feedback contact: editorial@rttnews.comBusiness News.

有关意见和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision in August 2023

2023年8月FDA决定面临的生物技术股票

Biotech Stocks Facing FDA Decision In June 2023

2023年6月FDA决定面临的生物技术股票

Biotech Stocks Facing FDA Decision In April 2023

2023年4月面临FDA决定的生物技术股票